Cancer remains the second-leading cause of death in the U.S., creating an urgent need to detect cancer at earlier stages when outcomes are better. With the emergence of novel multi-cancer screening technologies, the potential public health impact may be substantial. Given these advances, is it time to rethink the way clinical trials are designed to assess the effectiveness of these screening technologies? Joining Dr. Charles Turck to discuss how we can utilize surrogate endpoints to evaluate the efficacy of cancer screening modalities is Dr. Eric Klein, a distinguished scientist at GRAIL.